BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cronin O, McKnight O, Keir L, Ralston SH, Hirani N, Harris H. A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease. Rheumatol Int 2021;41:921-8. [PMID: 33721094 DOI: 10.1007/s00296-021-04835-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Albrecht K, Strangfeld A, Marschall U, Callhoff J. Interstitial lung disease in rheumatoid arthritis: incidence, prevalence and related drug prescriptions between 2007 and 2020. RMD Open 2023;9. [PMID: 36669830 DOI: 10.1136/rmdopen-2022-002777] [Reference Citation Analysis]
2 Nasonov EL, Ananyeva LP, Avdeev SN. Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology. Naučno-praktičeskaâ revmatologiâ 2022;60:517-534. [DOI: 10.47360/1995-4484-2022-1] [Reference Citation Analysis]
3 Klemm P, Henes J, Xanthouli P. Interstitielle Lungenbeteiligung bei der rheumatoiden Arthritis. Arthritis und Rheuma 2022;42:324-329. [DOI: 10.1055/a-1893-4857] [Reference Citation Analysis]
4 Tsujii A, Isoda K, Yoshimura M, Nakabayashi A, Kim D, Tamada T, Yamamoto K, Ohshima S. Comparison of safety and efficacy between Janus kinase inhibitors and abatacept for rheumatoid arthritis-associated interstitial lung disease.. [DOI: 10.21203/rs.3.rs-2110699/v1] [Reference Citation Analysis]